vimarsana.com

Patients With Relapsed Refractory Diffuse Largeb Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Sabarish ram ayyappanRegeneron pharmaceuticalsEuropean organization for research of cancerCity of hope cancer treatment centerRam ayyappanHope cancer treatment centerEuropean organizationAnn arborPrescription drug user fee actDiffuse largeb cell lymphomaFollicular lymphomaPrespecified analysisPivotal phasePatients with relapsed refractory diffuse largeb cell lymphomaElm 2 trial

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Little rockUnited statesUniversity of arkansasAakash mukherjeeDepartment of internal medicineCollege of medicineWinthropp rockefeller cancer instituteWinthropp rockefeller cancer institute transplant centerCancer institute transplant centerCancer instituteMedical sciencesInternal medicineContributing kiteRelapsed refractoryb cell lymphomaPatients with relapsed refractory diffuse largeb cell lymphomaScholar 1 study

Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Carmelo carlo stellaDepartment of oncologyDepartment of biomedical sciencesHumanitas universityHumanitas research hospitalBiomedical sciencesResearch hospitalFda approval of glofitamabPatients with relapsed refractory diffuse largeb cell lymphomaPhase 1 2 np30179 trial

Tafasitamab Plus Lenalidomide Has Continued Efficacy and Safety in R/R DLBCL

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

United kingdomHospira incyteNagesh kalakondaSpeaker bureauUniversity of liverpoolInternational prognostic indexAnn arborTafasitamab and lenalidomide followed by maintenancePatients with relapsed refractory diffuse largeb cell lymphomaL mind trialThe university of liverpool

vimarsana © 2020. All Rights Reserved.